RY 133.62 0.2325% TD 80.66 0.3608% SHOP 96.69 -2.3432% CNR 170.96 1.5503% ENB 49.46 1.228% CP 112.45 0.196% BMO 126.9 -0.2672% TRI 208.55 -0.2583% CNQ 106.0 0.5406% BN 54.95 -1.0267% ATD 77.31 -0.3609% CSU 3649.3 -1.2892% BNS 63.12 -1.5596% CM 64.92 -0.3683% SU 54.025 0.4369% TRP 49.43 0.5288% NGT 59.66 12.8428% WCN 226.31 -0.593% MFC 31.94 -0.6532% BCE 44.92 -0.817%
The Offer
Company Overview
BlinkLab, established on August 17, 2021, aims to expedite the development and commercialization of intellectual property (Licenced IP) from Princeton University. The company holds an exclusive global license for the Licenced IP, focusing on smartphone-neurobehavioral testing. BlinkLab has created a medical device, the BlinkLab Device, in the form of a smartphone application with an e-platform. This device conducts neurometric tests aiding in the diagnosis of conditions like autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia, and other neurodevelopmental disorders. The BlinkLab Tests, including eyeblink conditioning, prepulse inhibition of acoustic startle, and habituation of eye blink response, serve as biomarkers for neurological and psychiatric disorders. Results from these tests are recorded on smartphones and analyzed using machine learning on BlinkLab's confidential and secure online platform. BlinkLab's immediate focus is to complete regulatory clinical studies and secure FDA approval in the US and CE Mark in Europe. The ultimate goal is to introduce the BlinkLab Device to the market initially as a diagnostic tool for ASD.
Xxxxxx Xxxxxx Xxxxxx
Xxxxxx Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx
Xxxxxx Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Enter your details below and our team will help you to decide if this product is best for you.
The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.
CA 
AU
UK
US
NZ
Please wait processing your request...